-+ 0.00%
-+ 0.00%
-+ 0.00%

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At IDWeek 2024

Benzinga·10/03/2024 12:21:56
Listen to the news

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024.

 

Presentation details can be found below:

Oral Presentation:

Title: Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections
Session: Mycology Matters: Insights into Fungal Infections
Date/Time: Thursday October 17, 2024 at 10:45 AM PDT
Location: Los Angeles Convention Center, Room 403 B
Presenting author: David A. Angulo, M.D., President and CEO of SCYNEXIS



Poster Presentation:

Title: SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential
Session: New Drug Development
Date/Time: Friday October 18, 2024 at 12:15 – 1:30 PM PDT
Location: Los Angeles Convention Center, Halls JK
Presenting author: David A. Angulo, M.D., President and CEO of SCYNEXIS



For more information, see the IDWeek website here.